BIOC - バイセプト （Biocept Inc.）

https://www.investing.com/news/assorted/biocept-to-offer-an-unspecified-amount-of-prefunded-warrants-and-warrants-to-purchase-common-stock-432SI-3061038

Biocept press release (BIOC): FY GAAP EPS of -$1.89 misses by $0.84.Revenue of $25.9M (-57.6% Y/Y) beats by $18.65M.Biocept reported cash of $12.9 million as of December 31,…

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update. “I could not be prouder of my Biocept colleagues as together we have worked tirelessly to streamline operations, prioritize decisions to advance our corporate mission and carefully manage expenditures. We are more convinced than ever that our proprietary CNSide™ assa

https://www.investing.com/news/pro/bioclinica-receives-investment-bank-analyst-rating-update-3055846

Biocept (BIOC) said the first patient was enrolled in a trial of its cerebrospinal fluid assay CNSide. Read more here

Biocept, Inc. (NASDAQ: BIOC) Q3 2022 earnings call dated Nov. 28, 2022

Biocept, Inc. (NASDAQ:NASDAQ:BIOC) Q3 2022 Earnings Conference Call November 28, 2022 4:00 PM ET Company Participants Jody Cain - LHA Investor Relations Sam Riccitelli - Chairman and…

Biocept press release (BIOC): Q3 GAAP EPS of -$0.04 beats by $0.27.Revenue of $5.59M (-68.0% Y/Y) misses by $2.27M.Biocept reported cash as of September 30, 2022 of $18.0…

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and ni

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms. Dao-Haddock is a certified public accountant (CPA) with more than 20 years of financial and accounting experience. She will serve on Biocept’s Audit Committee. “Quyen’s extensive financial experience leading accounting and finan

Plus Therapeutics (PSTV) signed a multi-year agreement to use Biocept''s (BIOC) cerebrospinal fluid ((CSF)) assay CNSide in its phase 1/2a trial called ReSPECT-LM of…

Biocept press release (BIOC): Q1 GAAP EPS of -$0.16 beats by $0.08.Revenue of $19.95M (+12.3% Y/Y) beats by $8.46M.Biocept reported cash and cash equivalents as of March 31, 2022…

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months

Biocept (BIOC) has reported a delay in the filing of its Q122 quarterly report on Form 10-Q.The delay is related to the ongoing accounting review of Biocept’s financial statements as of…

Pune, April 07, 2022 (GLOBE NEWSWIRE) -- Global Liquid Biopsy Market report is expert study that can deliver you with an elaborate analysis of the Liquid Biopsy. The report covers information about top players, projected size of the market, data and figures to update about where opportunities are in the market, competitor analysis and vendor information. Also, it offers a complete analysis of the key market dynamics, with growth drivers, challenges, restraints, opportunities and trends. Furthermore, receive exact details and statistics associated to Liquid Biopsy market and its key factors such as revenue, growth, compound annual growth, year-over-year developments, consumption, and production. The advantages of liquid biopsy over solid tumor biopsy, rising prevalence of cancer, increasing preference for non-invasive procedures, growing public and private funding to support research activities in the field of liquid biopsy and favorable government initiatives, are some of the factors expected to propel the growth of liquid biopsy market in the coming years.